echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Blood: Treatment of B-ALL in Children and Young Adults with CD19/22 CAR T Cells

    Blood: Treatment of B-ALL in Children and Young Adults with CD19/22 CAR T Cells

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The persistence of remission in single-antigen-targeted chimeric antigen receptor (CAR) T cells is limited by antigen modulation, which can be overcome by combined targetin.


    The primary endpoints of the study were toxicity and definitive dos.



    A total of 20 B-ALL patients, aged 4 to 36 years, were recruited and all received CD12BBz therap.


    The limited CAR T cell expansion and persistence of MSCV-CD12BBz compared to EF1a-CD2BBz prompted the laboratory to compare the promoters of EF1a and MSCV, but found no significant differenc.


    In conclusion, this study demonstrates the safety and efficacy of CD12BBz in a CAYA B-ALL cohort, while further optimizing combinatorial antigen targeting to help overcome well-defined limitation.


     

    Original source:

    Shalabi Haneen, Qin Haiying, Su Angela et a.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.